Diridavumab

Diridavumab is a monoclonal antibody designed for the treatment of Ebola virus disease. It was developed by Mapp Biopharmaceutical and is considered one of the most effective treatments for Ebola.

History

Diridavumab was first developed in response to the 2014-2016 Ebola virus epidemic in West Africa. It was fast-tracked for approval by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) due to the urgent need for an effective treatment for Ebola.

Mechanism of Action

As a monoclonal antibody, diridavumab works by binding to the Ebola virus and neutralizing it. This prevents the virus from entering host cells and replicating, thereby stopping the progression of the disease.

Clinical Trials

Several clinical trials have been conducted to test the safety and efficacy of diridavumab. These trials have shown that diridavumab is safe and effective in treating Ebola virus disease.

Side Effects

Like all medications, diridavumab can cause side effects. The most common side effects include fever, headache, and fatigue. However, these side effects are generally mild and go away on their own.

Availability

Diridavumab is currently available under an Emergency Use Authorization (EUA) from the FDA. This means that it can be used in emergency situations where there are no other available treatments.

See Also

• Monoclonal antibodies
• Ebola virus disease
• Mapp Biopharmaceutical
• Food and Drug Administration
• European Medicines Agency

Diridavumab Resources
Latest articles Most recent articles Ongoing trials	Wikipedia